Editorial
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
Abstract
Immune checkpoint inhibitors (ICIs) utilize the natural programming of the immune system to initiate an antitumor response, counteracting checkpoint molecule expression on tumor cells (1).
